This is a standard inducement grant for a new executive hire. No financial results or guidance were released. Monitor the next quarterly filing for any operational updates or changes in strategy under the new CFO.
Drugs in focus
SNDX drug pipeline →Niktimvo
▲ Bullish Named in this press release- Impact
- Phase
- Approved
- Time to market
- Already approved and commercially launched (FDA approved August 2024)
- Next catalyst
- None dated
What to watchNiktimvo's commercial trajectory is the primary value driver for SNDX on this drug. Watch Q2/Q3 2026 net revenue prints for signs of continued ramp ($151.6M FY2025 annualizing to ~$220M in Q1 2026). The Phase 2 IPF readout in Q4 2026 is an important optionality catalyst that could open a much larger market, but comes with clinical risk. The $250M convertible note issued June 2026 introduces modest dilution overhang (~8-10% of shares outstanding).
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+1- T+0 · Nov 10 $9.49entry
- T+1 · 6d ago +1.05%α −0.27% · $9.59
- T+4 · todayOpen
- T+5 · in 5h Pending
- T+20 · in 22d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
Syndax Pharmaceuticals issued a press release announcing an inducement stock option award of 270,000 shares to its new CFO, Aaron A. Ondrey, as material to his employment. This is a routine compensation event with no financial results or guidance, and does not affect the company's operations or outlook.
Key Facts
- Aaron A. Ondrey appointed CFO effective November 9, 2026, announced November 2, 2026.
- Inducement award: option to purchase 270,000 shares at $9.55 per share (closing price on grant date).
- Option vests over four years: 25% after one year, then monthly over 36 months.
- Award approved by Board under Nasdaq Listing Rule 5635(c)(4) as inducement material to employment.
Financial Impact
270,000 shares at $9.55 per share = approximately $2.58 million in potential value if fully vested and exercised, but no immediate cash impact.
Risk Factors
- No financial data or guidance provided in this filing.
- Dilution from the option award is minimal relative to outstanding shares.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3399074 |
Track record
16 reports on SNDX
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 12, 20264d ago 3 Neutral 1/10 Entry $9.45 Now $9.13 −3.39% settles Feb 11
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $9.49 Now $9.13 −3.79% settles Feb 8
- Nov 9, 20267d ago Press Release Neutral 2/10 Viewing Entry $9.49 Now $9.13 −3.79% settles Feb 8
- Nov 2, 202614d ago 8-K Neutral 5/10 No price data
- Nov 2, 202614d ago Press Release Neutral 2/10 No price data
- Nov 2, 202614d ago Press Release Neutral 5/10 Entry $14.29 Now $9.13 −36.11% settles Feb 1
- Oct 29, 202618d ago 144 Neutral 2/10 Entry $13.65 Now $9.13 −33.11% settles Jan 28
- Jul 14, 202617w ago 8-K Bullish 7/10 Entry $24.13 to $17.03 Now $9.13 −62.16% ▼ −29.42% −32.80% vs SPY
- Jul 1, 202619w ago Press Release Neutral 2/10 Entry $21.82 to $18.20 Now $9.13 −58.16% ▼ −16.59% −20.16% vs SPY
- Jun 11, 202622w ago Press Release Bullish 7/10 Entry $17.91 to $20.56 Now $9.13 −49.02% ▲ +14.80% +10.40% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers